Here are four things to know.
1. Ogivri is a biosimilar version of Genentech’s cancer drug Herceptin.
2. The drug is intended to treat patients with breast or metastatic stomach cancer.
3. Ogivri is the second biosimilar approved for cancer, and the first approved to treat stomach and breast cancer.
4. Both Ogivri and Herceptin contain a boxed warning over an increased risk of heart disease, infusion reactions, lung damage and harm to fetuses.
More articles on supply chain:
Pfizer to launch generic version of Viagra at $33 per pill
FDA urges drugmaker to recall osteoarthritis product following liver and lung injury reports
Amazon withdraws application for pharmacy license in Maine
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
